163 related articles for article (PubMed ID: 22078327)
1. Role and expression of FRS2 and FRS3 in prostate cancer.
Valencia T; Joseph A; Kachroo N; Darby S; Meakin S; Gnanapragasam VJ
BMC Cancer; 2011 Nov; 11():484. PubMed ID: 22078327
[TBL] [Abstract][Full Text] [Related]
2. The fibroblast growth factor receptor substrate 3 adapter is a developmentally regulated microtubule-associated protein expressed in migrating and differentiated neurons.
Hryciw T; MacDonald JI; Phillips R; Seah C; Pasternak S; Meakin SO
J Neurochem; 2010 Feb; 112(4):924-39. PubMed ID: 19943849
[TBL] [Abstract][Full Text] [Related]
3. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
4. Genomic organization and comparative sequence analysis of the mouse and human FRS2, FRS3 genes.
Zhou L; McDougall K; Kubu CJ; Verdi JM; Meakin SO
Mol Biol Rep; 2003 Mar; 30(1):15-25. PubMed ID: 12688531
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
6. Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer.
Kachroo N; Valencia T; Warren AY; Gnanapragasam VJ
Br J Cancer; 2013 Feb; 108(3):597-601. PubMed ID: 23169297
[TBL] [Abstract][Full Text] [Related]
7. Trk receptor binding and neurotrophin/fibroblast growth factor (FGF)-dependent activation of the FGF receptor substrate (FRS)-3.
Dixon SJ; MacDonald JI; Robinson KN; Kubu CJ; Meakin SO
Biochim Biophys Acta; 2006 Apr; 1763(4):366-80. PubMed ID: 16697063
[TBL] [Abstract][Full Text] [Related]
8. FGF-Dependent, Context-Driven Role for FRS Adapters in the Early Telencephalon.
Nandi S; Gutin G; Blackwood CA; Kamatkar NG; Lee KW; Fishell G; Wang F; Goldfarb M; Hébert JM
J Neurosci; 2017 Jun; 37(23):5690-5698. PubMed ID: 28483978
[TBL] [Abstract][Full Text] [Related]
9. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
[TBL] [Abstract][Full Text] [Related]
10. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.
Wang XH; Wu HY; Gao J; Wang XH; Gao TH; Zhang SF
Brain Res; 2019 Feb; 1704():219-228. PubMed ID: 30321496
[TBL] [Abstract][Full Text] [Related]
11. FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway.
Zhou W; Feng X; Wu Y; Benge J; Zhang Z; Chen Z
Cell Res; 2009 Oct; 19(10):1165-77. PubMed ID: 19652666
[TBL] [Abstract][Full Text] [Related]
12. The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.
Ranzi V; Meakin SO; Miranda C; Mondellini P; Pierotti MA; Greco A
Endocrinology; 2003 Mar; 144(3):922-8. PubMed ID: 12586769
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
Hanes R; Munthe E; Grad I; Han J; Karlsen I; McCormack E; Meza-Zepeda LA; Stratford EW; Myklebost O
Cells; 2019 Feb; 8(2):. PubMed ID: 30795553
[No Abstract] [Full Text] [Related]
14. Neurotrophin and FGF Signaling Adapter Proteins, FRS2 and FRS3, Regulate Dentate Granule Cell Maturation and Excitatory Synaptogenesis.
Nandi S; Alviña K; Lituma PJ; Castillo PE; Hébert JM
Neuroscience; 2018 Jan; 369():192-201. PubMed ID: 29155277
[TBL] [Abstract][Full Text] [Related]
15. MiR-140-5p and miR-92a-3p suppress the cell proliferation, migration and invasion and promoted apoptosis in Wilms' tumor by targeting FRS2.
Li JL; Luo P
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):97-108. PubMed ID: 31957822
[TBL] [Abstract][Full Text] [Related]
16. Developmental stage-specific role of Frs adapters as mediators of FGF receptor signaling in the oligodendrocyte lineage cells.
Furusho M; Ishii A; Hebert JM; Bansal R
Glia; 2020 Mar; 68(3):617-630. PubMed ID: 31670856
[TBL] [Abstract][Full Text] [Related]
17. Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer: a working hypothesis.
Assinder SJ; Beniamen D; Lovicu FJ
Biomed Res Int; 2015; 2015():827462. PubMed ID: 26075267
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth.
Santhana Kumar K; Brunner C; Schuster M; Kopp LL; Gries A; Yan S; Jurt S; Moehle K; Bruns D; Grotzer M; Zerbe O; Schneider G; Baumgartner M
Cell Oncol (Dordr); 2023 Apr; 46(2):331-356. PubMed ID: 36495366
[TBL] [Abstract][Full Text] [Related]
19. Developmental expression patterns of the signaling adapters FRS-2 and FRS-3 during early embryogenesis.
McDougall K; Kubu C; Verdi JM; Meakin SO
Mech Dev; 2001 May; 103(1-2):145-8. PubMed ID: 11335123
[TBL] [Abstract][Full Text] [Related]
20. Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells.
Zhang L; Zhao Z; Xu S; Tandon M; LaValle CR; Deng F; Wang QJ
Oncotarget; 2017 Feb; 8(8):12800-12811. PubMed ID: 28077787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
